the advantage that LCT has over that study (puting aside the small singular 4 patients) is this:
"NTCELL’s ability to decrease UPDRS by an average of 14 points after 81 weeks is clinically significant, representing a 2.8 to 3.5 year reversal of neurological deterioration. In the first patient the improvement is sustained at 130 weeks after NTCELL implant."
http://www.businesswire.com/news/ho...ogies-NTCELL®-Demonstrates-Continued-Reversal
you get bonus points if your study had multiple placebo at 81 weeks too !!
Ann: Appendix 4C - quarterly, page-10
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 1AI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.81M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.8¢ | 0.7¢ | $6.268K | 895.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 4707556 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1255620 | 12 |
View Market Depth
| Last trade - 15.50pm 12/09/2024 (20 minute delay) ? |
| 1AI (ASX) Chart |